IP Library › Granted Patent US 12,449,421
Granted Patent B1
US 12,449,421 · App. 19/251,906 · Granted Oct 21, 2025

Anti-CD79B protein monoclonal antibody, products containing the same, and uses thereof

Inventors: Tongyu Lin (Chengdu, CN); Yang Liu (Chengdu, CN); Zongyao Huang (Chengdu, CN); Huangming Hong (Chengdu, CN); Junxuan Zhu (Chengdu, CN); Jun Hou (Chengdu, CN); Dan Luo (Chengdu, CN); Jingcheng Luo (Chengdu, CN)
Assignee: Sichuan Cancer Hospital
G01N33/577C07K16/2803G01N33/6872C07K2317/565C07K2317/567G01N2333/70503
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,449,421
App. No.
19/251,906
Granted
Oct 21, 2025
Kind
B1
Abstract

An anti-CD79B protein monoclonal antibody and related products and uses thereof are disclosed. The anti-CD79B protein monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain includes a heavy chain variable region, and the light chain includes a light chain variable region. The heavy chain variable region includes complementary-determining regions CDR1, CDR2, and CDR3 with amino acid sequences as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively. The light chain variable region comprises complementary-determining regions CDR1, CDR2, and CDR3 with amino acid sequences as shown in SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, respectively. The anti-CD79B protein monoclonal antibody exhibits high specificity and sensitivity, enabling specific recognition of cells expressing CD79B protein. It is suitable for immunological detection, and effectively prevents false-positive and false-negative results in immunological assays, thereby further improving the accuracy of detection and diagnostic outcomes.

Claims (6)

1. An anti-CD79B protein monoclonal antibody, comprising a heavy chain and a light chain, wherein the heavy chain includes a heavy chain variable region; the light chain includes a light chain variable region; the heavy chain variable region comprises complementary-determining regions CDR1, CDR2, and CDR3 having amino acid sequences as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively; and the light chain variable region comprises complementary-determining regions CDR1, CDR2, and CDR3 having amino acid sequences as shown in SEQ ID NO:9, SEQ ID NO:10, and SEQ ID NO:11, respectively.

2. The anti-CD79B protein monoclonal antibody according to claim 1 , wherein the heavy chain variable region further comprises framework regions FR1, FR2, FR3, and FR4 having amino acid sequences as shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7, respectively.

3. The anti-CD79B protein monoclonal antibody according to claim 1 , wherein the light chain variable region further comprises framework regions FR1, FR2, FR3, and FR4 having amino acid sequences as shown in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, and SEQ ID NO:15, respectively.

4. The anti-CD79B protein monoclonal antibody according to claim 1 , wherein the heavy chain has an amino acid sequence as shown in SEQ ID NO:8; and the light chain is has an amino acid sequence as shown in SEQ ID NO:16.

5. A reagent for detecting CD79B protein, comprising the anti-CD79B protein monoclonal antibody as claimed in claim 1 .

6. A reagent for detecting CD79B protein, comprising the anti-CD79B protein monoclonal antibody as claimed in claim 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2025
From: LIN, TONGYU; LIU, YANG; HUANG, ZONGYAO; HONG, HUANGMING; ZHU, JUNXUAN; HOU, JUN; LUO, DAN; LUO, JINGCHENG
To: SICHUAN CANCER HOSPITAL
Reel/Frame 071754/0421 →
Priority Claims (1)
CN 202510337343.5 · Mar 21, 2025 · national
References Cited (21)
US 9737623B2 · Desnoyers et al. · 2017 [cited by examiner]
US 10494432B2 · Chen et al. · 2019 [cited by examiner]
US 10981987B2 · Chen et al. · 2021 [cited by applicant]
US 11255865B2 · Ganz et al. · 2022 [cited by examiner]
US 11866496B2 · Chen et al. · 2024 [cited by examiner]
US 20090068202A1 · Chen et al. · 2009 [cited by applicant]
US 20220315663A1 · Ganesan et al. · 2022 [cited by examiner]
US 20230183371A1 · Chu et al. · 2023 [cited by examiner]
AU 2012200923B2 · 2014 [cited by applicant]
CN 101802013A · 2023 [cited by applicant]
CN 118557750A · 2024 [cited by applicant]
WO 2021076196A · 2021 [cited by applicant]
Office Action, CN Pat. Appl. No. 202411110872.3, dated Apr. 23, 2025; issued by the China National Intellectual Property Administration (ISA/CN), Beijing, China. [cited by applicant]
Notice of Grant of Invention Patent Rights, CN Pat. Appl. No. 202411110872.3, dated Jun. 13, 2025; issued by the China National Intellectual Property Administration (ISA/CN), Beijing, China. [cited by applicant]
Zarrineh et al., “Mechanism of antibodies purification by protein A,” Analytical Biochem., vol. 609, 113909; Nov. 15, 2020; doi.org/10.1016/j.ab.2020.113909. [cited by applicant]
Dornan et al., “Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma,” Blood, 114 (13): 2721-2729; 2009; doi.org/10.1182/blood-2009-205500. [cited by applicant]
Zheng et al., “In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates,” Mol Cancer Ther 2009;8(10). Oct. 2009. [cited by applicant]
Chu F, et al., “Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas,” J Immunother Cancer 2023;11:e007515. doi:10.1136/jitc-2023-007515. [cited by applicant]
Yang et al., “An antibody-drug conjugate in treating diffuse large B-cell lymphoma: polatuzumab vedotin,” Chin J New Drugs Clin Rem, 1007-7669 (2020) 06-0346-03; DOI: 10.14109/j.cnki.xyylc.2020.06.05. [cited by applicant]
Rathore et al., “Purification of Therapeutic Antibodies by Protein A Affinity Chromatography,” Methods Mol. Biol., 2022:2313:169-177; doi: 10.1007/978-1-0716-1450-1_9. [cited by applicant]
Mjias-Gomez et al., “A window into the human immune system: comprehensive characterization of the complexity of Antibody complementary-determining regions in functional antibodies,” MAbs; Oct. 24, 2023; 15(1):2268255; d… [cited by applicant]